Toxic megacolon
British Journal of Surgery · 02.08.2024 · 111 (8)
DOI: 10.1093/bjs/znae200 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Surgery, online erschienen am 09.08.2024. Verfasst von Orestis Argyriou und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Colorectal Surgery, St Mark's National Bowel Hospital & Academic Institute, London, UK. Hauptthemen laut MEDLINE: Megacolon, Toxic. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 20 Literaturangaben.
Abstract (Originalsprache)
Toxic megacolon is a potentially life-threatening condition, most commonly caused by inflammatory bowel disease Timely recognition of the disease and intervention is critical to avoid perforation Guidelines recommend contrast CT imaging as the preferred investigation for patients in whom a concern about toxic megacolon exists Surgery is indicated for patients with haemodynamic instability, in the presence of perforation, necrosis, or full thickness ischaemia, or for patients refractory to initial medical measures Toxic megacolon is a potentially lethal condition characterized by total or segmental non-obstructive colonic dilatation1. It is most commonly associated with inflammatory bowel disease (IBD); however, any inflammatory or infectious condition of the bowel can lead to toxic megacolon. Whilst other conditions can cause colonic dilatation, ‘toxic’ refers to the presence of sepsis and therefore toxic megacolon requires a high level of suspicion and prompt management, due to the risk of impending perforation and the sepsis-related high morbidity and mortality. Despite studies investigating the incidence of toxic megacolon in the IBD population (with somewhat conflicting reports), the exact incidence in the general population remains unknown2. IBD is the leading predisposing factor for toxic megacolon, being present in approximately 48% of cases3. Nevertheless, the literature suggests a decreasing incidence of IBD-related toxic megacolon, perhaps due to improved monitoring by allied healthcare professionals, patient education, and advancements in IBD management. Historically, ulcerative colitis has been considered the main aetiological factor. However, the published evidence is conflicting as to whether Crohn’s disease or ulcerative colitis carries a bigger risk1,3. The epidemiology is shifting towards infectious causes, with a particular emphasis on Clostridioides difficile colitis. Worldwide, the incidence of C. difficile infection is as high as 631.8 per 100 000 population per year, associated with increased use of antibiotics and ageing populations4. For patients with C. difficile infection, the incidence of related toxic megacolon is reported to be as high as 4.3%2. Other infectious causes of toxic megacolon include other bacteria (Salmonella, Shigella, Yersinia, and the enterohaemorrhagic strains of Escherichia coli (O157)), parasites (Entamoeba histolytica and Cryptosporidium), viruses (cytomegalovirus 15), and fungi (Aspergillus)5. Cytomegalovirus is the most common organism causing toxic megacolon in the HIV population and is also frequently identified in IBD patients. Similarly to C. difficile infection, cytomegalovirus infection is more prevalent in the IBD population, due to the altered gut microbiome, exposure to immunosuppressive agents, frequent hospitalizations, and antibiotic administration, thus increasing the overall risk for development of toxic megacolon. Other less common causes of toxic megacolon include neutropenic colitis, ischaemic colitis, radiation-induced colitis, colonic lymphoma, Hirschsprung disease, and gastrointestinal graft versus host disease6. Toxic megacolon can occur at any age, with no sex or ethnicity predisposition. However, it typically affects adults between 30 and 50 years old and has a higher incidence in Ashkenazi Jews, probably due to the higher incidence of IBD in this population. The reported mortality rate associated with toxic megacolon is variable and ranges from 6% to 80%7,8. Colonic perforation is a strong predictor of mortality, with reports of at least 40%1. Variability is also noted with regards to the timing of surgical intervention, with reports suggesting better mortality rates with earlier surgical intervention9. Given the lack of pathognomonic signs for toxic megacolon, a diagnosis should be reached via a combination of comprehensive history taking (to establish the presence of IBD or risk factors for infective colitis), clinical examination (to look for signs of acute abdominal pathology in the presence of sepsis), laboratory findings (to demonstrate inflammation and sepsis), and imaging findings (to confirm colonic dilatation and inflammatory stranding), as summarized in Fig. 1 and discussed below. Diagrammatic representation of the components in the diagnosis of toxic megacolon IBD, inflammatory bowel disease. Patients with a suspected diagnosis of toxic megacolon will demonstrate non-specific signs and symptoms of an acute abdominal condition, in addition to signs of toxicity and sepsis. Clinical features include: non-specific symptoms (abdominal pain, diarrhoea, haematochezia, emesis, and abdominal distention); and signs and symptoms of toxicity (fever, tachycardia, and hypovalaemia). Timely diagnosis of toxic megacolon is critical; patients present acutely unwell. The potential common differential diagnoses include: Ogilvie’s syndrome/pseudo-obstruction; inflammatory, infective, or ischaemic colitis; colonic obstruction; and visceral perforation. The European Crohn’s and Colitis Organisation (ECCO) and the European Society of Gastrointestinal and Abdominal Radiology (ESGAR) recommend CT imaging as the modality of choice for patients with suspected toxic megacolon10. Key findings of CT imaging include (Fig. 2): colonic distension greater than 6 cm; loss of haustrae; nodular pseudopolyps; diffuse colonic wall thickening; segmental colonic wall thinning; concertina sign; peri-colonic fat stranding; ascites and pleural effusion; and gastric and small bowel distension5. Key findings of Toxic Megacolon on CT Imaging a Circumferential wall thickening (arrow) of a distended colon. b Submucosal oedema (large arrows) and ascites (arrow head). c Accordion sign (large arrows) and ascites (arrow head). d Left colon wall thickening with submucosal oedema (arrow heads), peri-colonic fat stranding and ascites (arrow), and dilated transverse colon (star); thinning of its wall is noted. e and f Abnormal haustral pattern with nodular pseudopolyps (arrow heads). Image from Eghbali et al.5. Historically, abdominal radiographs have played a role in the assessment of colonic dilatation, typically being used in serial examination every 12–24 h to monitor the progression of colonic dilatation (Fig. 3). In contemporary practice, CT imaging is more readily available, particularly in the Western world, and is therefore probably superior to plain radiography1,5,6,10,11. Dilated transverse colon with loss of haustrae, typically seen in patients with toxic megacolon Image from Ong et al.11. Blood tests will reflect the severity of inflammation (leucocytosis with neutrophilia) and electrolyte disturbances caused by diarrhoea, as well as protein loss (hypoalbuminaemia) and blood loss (anaemia) from the inflamed colon and, latterly, markers of organ failure. Nevertheless, none is diagnostic of toxic megacolon and can be encountered in a variety of acute gastrointestinal conditions. Stool samples should be sent for microscopy, culture, and susceptibility testing, and should be tested for the presence of C. difficile toxins. The diagnosis of C. difficile infection requires: the presence of diarrhoea (three or more unformed stools in 24 h); and a positive stool test for toxigenic C. difficile or its toxins, or colonoscopic/histopathological findings demonstrating pseudomembranous colitis12. Care should be taken in appropriate requesting and interpretation of C. difficile tests, to avoid falsely diagnosing C. difficile colitis, due to positive antigen tests, as these only indicate previous infection. The management of a patient with toxic megacolon can be broadly classified into initial resuscitation, aetiology-specific medical management, and surgical intervention. Initial resuscitation involves fluid resuscitation, correction of life-threatening electrolyte disturbances, and support of haemodynamic instability, when required, in collaboration with the ICU. Medical management aims to reduce colonic dilatation, restore normal colonic motility, and mitigate the risk of perforation1, while also providing aetiology-specific treatments. In IBD patients, when toxic megacolon is subsequent to acute severe ulcerative colitis, intravenous steroids should be administered according to local protocols and international guidelines. Close collaboration between members of the multidisciplinary team, especially between surgeons and gastroenterologists, is recommended with serial assessments and dynamic decision-making, to identify the optimal time point for surgical intervention. For patients with a C. difficile infection, medical management consists of withdrawal of any antibiotics that led to it and commencement of directed antibiotic treatment, usually with vancomycin and fidaxomicin in the UK, but undertaken in accordance with local guidelines. Although the aim of medical therapy is to reduce the need for surgical management, outcomes are often poorer with delayed surgery and, as with acute severe ulcerative colitis, a balance between intervening surgically too early and too late is key. Timed surgical intervention is indicated for toxic megacolon patients with concurrent haemodynamic instability, in the presence of perforation, necrosis, or full thickness ischaemia, or for patients refractory to initial medical measures1. As no specified guidance exists on the intraoperative considerations in toxic megacolon, and given the similarities and frequent coexistence with acute severe ulcerative colitis, pertinent national and international guidelines can be followed. The British Society of Gastroenterology (BSG) guidelines state that a subtotal colectomy with an end ileostomy and long rectal stump is the procedure of choice13; this facilitates the formation of a mucous fistula or the subcutaneous placement of the stump, as well as the preservation of the rectal planes for any future reconstructive surgery14. These guidelines and the ECCO guidelines add that this can be done via a minimally invasive approach, depending on local expertise. The guidelines refer to emergent rather than emergency cases, with very few studies published regarding emergency laparoscopic colectomy for patients with ulcerative colitis15; therefore, in the setting of toxic megacolon the authors advocate that an open approach is the safest and most appropriate option. When performing a subtotal colectomy and ileostomy in this scenario, technical considerations include omental preservation when feasible (when the colon is adherent to the omentum, the omentum should not be mobilized, as this risks microperforations being uncovered) and the preservation of the inferior mesenteric artery (IMA), to allow adequate blood supply to a long rectal stump13,16. A decision will need to be made about how to manage the rectal stump. Three ways are described in the ECCO and the American Society of Colon and Rectal Surgeons (ASCRS) guidelines17, including: intra-peritoneal stump closure (Hartmann’s pouch), subcutaneous siting of the closed rectal stump; and mucous fistula formation. The aim is to prevent intra-abdominal stump ‘blowout’, the risk of which may be as high as 33%18. Exteriorization or subcutaneous placement appears to reduce the risk of pelvic sepsis19,20, but there is no high-quality randomized evidence available to guide decision-making. The use of a rectal catheter or tube, in cases of intra-peritoneal stump closure, is advocated in the BSG guidelines. A rectal tube is typically a flexible 30Ch catheter inserted into the rectum and secured to the leg, with a silk stich. Toxic megacolon is a potentially life-threatening condition with high mortality, particularly in high-risk individuals and where perforation occurs. Prompt diagnosis and management are imperative and require a high level of suspicion and multidisciplinary decision-making. The authors have no funding to declare. The authors declare no conflict of interest. Orestis Argyriou (Writing—original draft, Writing—review & editing), Gita Lingam (Writing—original draft, Writing—review & editing), Phil Tozer (Writing—review & editing), and Kapil Sahnan (Supervision, Writing—review & editing)
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Colorectal Surgery, St Mark's National Bowel Hospital & Academic Institute, London, UK.
- Department of Surgery and Cancer, Imperial College London, London, UK.
ORCID-Profile: Orestis Argyriou, Phil Tozer
Zitieren
APA
Argyriou, O., Lingam, G., Tozer, P., & Sahnan, K. (2024). Toxic megacolon. British Journal of Surgery, 111(8). https://doi.org/10.1093/bjs/znae200
Vancouver
Argyriou O, Lingam G, Tozer P, Sahnan K. Toxic megacolon. British Journal of Surgery. 2024;111(8). doi:10.1093/bjs/znae200
BibTeX
@article{Argyriou2024,
author = {Argyriou, Orestis and Lingam, Gita and Tozer, Phil and Sahnan, Kapil},
title = {Toxic megacolon},
journal = {British Journal of Surgery},
year = {2024},
volume = {111},
number = {8},
doi = {10.1093/bjs/znae200}
}
EUVIMED